NCT07244341
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Trial sites expanded: 19 → 29 locations
- Secondary endpoints: details revised at 2 of 9 entries
- Minor Trial sites expanded: 6 → 19 locationsv4
- Minor Study sites: 3 to 6v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Nov 20, 2025 to Dec 3, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)
Timeframe: Day 1 up to Day 28
Part 1 and 2: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)
Timeframe: From Screening up to approximately 5 years
Secondary (9)
Prostate-Specific Antigen (PSA) 50 Response Rate
Prostate-Specific Antigen (PSA) 90 Response Rate
Prostate-Specific Antigen (PSA) Nadir Response Rate
Radiographic Progression-Free Survival (rPFS)
Overall Survival (OS)
Show 4 moreShow less
Time to PSA Progression
Objective Response Rate (ORR)
Time to First SSRE (symptomatic bone fractures, spinal cord compression, surgery, or radiation to the bone, whichever is first)
Total and Unbound Plasma Concentration of Valemetostat in Combination with Darolutamide
Arms and interventions
Part 1 (Dose Escalation)Experimental
Participants will receive valemetostat at escalating doses in combination with darolutamide.
Part 2 (Dose Expansion)Experimental
Participants will receive valemetostat at 2 or more dose levels in combination with darolutamide.
Drugs: Valemetostat, Darolutamide
Sites
29 sites in 7 countries
United States 9, China 5, Australia 4, Japan 4, Spain 4, France 2, Ireland 1